Drug intelligence / Profile preview

Ceteric

Development stage: Phase 1
Lead developer: Seattle Gummy Company
Modality: Small Molecules
Administration: Oral

Overview

Ceteric is a gummy formulation of cetirizine hydrochloride, a second-generation antihistamine developed by Seattle Gummy Company. It is indicated for the relief of symptoms associated with seasonal and perennial allergic rhinitis, as well as chronic idiopathic urticaria. As a selective H1-receptor antagonist, cetirizine inhibits the interaction of histamine with H1 receptors on effector cells, thereby reducing allergic responses such as sneezing, pruritus, and watery eyes. The gummy delivery system is intended to improve patient compliance and provide a convenient, waterless alternative to traditional tablets or liquid formulations.

Brand names: Ceteric
Other names: cetirizine HCl Gummycetirizine gummy

Targets

HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on Ceteric.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ceteric.

Explore the full profile